Search

1,968 items · By date added

Bank of America: Tonghuashun’s third-quarter results beat BofA expectations, but cash receipts and contract liabilities point to cooling growth

Tonghuashun’s net profit rose 53% year on year in the third quarter of 2026, benefiting from business growth and deferred revenue recognition. However, growth in sales cash receipts slowed to 9%, and contract liabilities fell 8% quarter on quarter. BofA maintained its Buy rating while cutting its earnings forecasts and target valuation, lowering its price target from 290 yuan to 255 yuan.

Bank of America: BofA software survey: AI’s share of budgets rises to 9.4%; returns and costs determine the pace of expansion

Software budgets are expected to grow 5.3% in 2027, with AI receiving both new funding and money reallocated from existing budgets. But only 17.2% of respondents have achieved measurable enterprise-wide returns; how much revenue cloud, security and application vendors capture depends on deployment costs and actual benefits.

Bank of America: BofA FX Weekly: Yen preferred for short euro positions as buffers thin for high-yielding emerging-market currencies

French risks are weighing on the euro, but pricing constraints affect both the dollar and sterling. BofA prefers to express a short euro position against the yen. Emerging-market carry returns have generally risen, masking the erosion of buffers in currencies that previously held up well.

Bank of America: BofA Global Rates Weekly: Flight to safety lifts bonds, but French spreads and rate-hike risks remain

A decline in risk assets supported US Treasuries, but BofA still expects a Federal Reserve rate hike. French government bonds lack new buyers, while the ECB faces pressure to reassure markets. Australian and Japanese rates trades depend on how much tightening is already priced in.

Bank of America: Doubts over AI returns weigh on Treasury yields, while the case for rate hikes in the US and Europe remains

US stocks fell as Treasury yields declined. BofA believes markets are worried about whether AI investment can be converted into profits. Risk aversion raises the bar for a Federal Reserve rate hike in October, but the energy shock and underlying inflation still support further tightening; the European Central Bank is more likely to wait, while the Bank of England faces more immediate pressure to act.

Bank of America: Memory price gains diverge as BofA sees scope for additional shareholder returns at Korean manufacturers

DRAM prices continue to strengthen, while consumer NAND is becoming subdued. BofA believes a shift in supply toward HBM and servers, together with low channel inventories, could extend the upcycle; growing cash flow at SK hynix and Samsung could support additional dividends and buybacks.

Bank of America: CTI: Pharmaceutical recovery and overseas expansion support growth; third-quarter gross margin falls below BofA expectations

CTI’s third-quarter revenue rose 14% year on year and net profit attributable to shareholders rose 15%, but gross margin fell below BofA’s forecast. The pharmaceutical business’s return to profitability, improved collections and overseas acquisitions support BofA’s medium-term growth outlook. BofA has slightly lowered its earnings forecasts and price target while maintaining its Buy rating.

Bank of America: Hesai’s shipment forecasts cut: Why does BofA still favor its new robotics business?

BofA cut its 2026 and 2027 earnings forecasts for Hesai by 44% and 22%, respectively, and lowered its price targets, but maintained its Buy rating. Automotive demand is weighing on current profits, while spatial cameras and actuator modules underpin its long-term view. The key is progress on orders and deliveries for the new businesses.

Bank of America: Glodon: Cost Controls Stabilize Third-Quarter Profit, but Revenue Recovery Still Lags BofA’s Expectations

Glodon’s third-quarter revenue fell 2% year on year, coming in 4% below BofA’s forecast; lower administrative expenses supported broadly flat profit. AI products are entering commercialization, but weak demand along the property value chain continues to weigh on the core business. BofA cut its earnings forecasts and maintained its Underperform rating.

Bank of America: Han’s Laser: 3C revenue already exceeds full-year expectations. Why did BofA still cut its target price?

Revenue from 3C equipment in the first three quarters already exceeded the market’s previous full-year expectation, and the company also secured its first orders for 3D printing equipment. But third-quarter profit fell sequentially. While maintaining its Buy rating, BofA cut its target price from 185 yuan to 152 yuan because of lower valuation multiples and free cash flow forecasts.

Bank of America: Meta’s advertising growth beats expectations as new AI businesses lift valuation and add cash pressure

Bank of America raised its revenue forecast and price target for Meta but slightly lowered its 2027 earnings-per-share estimate: advertising is benefiting from AI, while Muse and enterprise services open up new revenue opportunities, but investment comes before monetization, and capital spending and financing pressure are both rising.

Bank of America: Kering: Gucci retail weakens again as BofA cuts earnings forecasts and price target

Kering’s third-quarter revenue met market consensus, but Gucci retail sales fell 9% year on year, missing expectations; wholesale shipments temporarily cushioned the decline. The company withdrew its full-year revenue growth guidance. BofA cut its price target from €280 to €250 and maintained its Neutral rating.

Bank of America: Why is BofA more optimistic about an upside surprise in 2027 after Abbott lowered its growth outlook?

BofA cut its forecast for Abbott’s 2027 comparable sales growth to 6% but maintained its buy rating: new electrophysiology products and expanded Libre reimbursement offer upside, while a nutrition spin-off could lift valuation. Pricing and competitive pressures have already affected recent growth.

J.P. Morgan: After the safe-haven rally in Treasuries, why does JPMorgan still expect yields to rise and the curve to steepen?

Pressure on French government bonds and weakness in technology stocks drove Treasuries higher, but JPMorgan believes near-term valuations have become expensive and prefers a trade betting on a wider spread between 10-year and 30-year yields. Auction data show that foreign and long-end demand remains strong, although buyers have become more price-sensitive across most maturities.

J.P. Morgan: Safe-haven demand lifts Treasuries as credit risks diverge: Why does JPMorgan still expect yields to rise slightly?

Pressure on European sovereign bonds and concerns over AI valuations are driving safe-haven demand for US Treasuries, but JPMorgan believes the 10-year yield is already about 15 basis points below its model-implied fair value. Credit market pressure is concentrated in major cloud providers and lower-rated bonds, while ABS and agency CMBS are relatively resilient.

J.P. Morgan: BeOne’s new lung cancer drug: Response rate declines, while durability and brain penetration data support continued development

After the BGB-58067 sample was expanded, the objective response rate fell from 31.7% to 25.3%. However, newly disclosed data on duration of response, progression-free survival and intracranial efficacy led JPMorgan to continue supporting a pivotal lung cancer study in 2027.

J.P. Morgan: Moderna: Can Early Pancreatic Cancer Data Support an 80 billion Dollar Valuation?

In the adjuvant pancreatic cancer data, 11 of 20 evaluable patients remained recurrence-free. JPMorgan believes the current efficacy evidence remains difficult to distinguish from chemotherapy alone, while Moderna’s valuation already incorporates expectations for broader indications and platform value.

J.P. Morgan: Merck’s phase III INT data strengthen melanoma outlook; kidney cancer results will determine scope for expansion

JPMorgan believes the full phase III INT data support broad use as adjuvant treatment after melanoma surgery; following the share price pullback, the market’s valuation of the program appears more reasonable. Next, phase II renal cell carcinoma data will influence its potential value in other cancers.

J.P. Morgan: Kering: Gucci retail slows again as resilience at other brands fails to offset profit forecast cuts

Third-quarter group sales matched consensus, but Gucci’s retail decline widened to 9%, with wholesale growth masking a divergence between channels. Other brands and jewelry performed better, but JPMorgan cut its price target to €200 as the recovery slowed, store closures weighed on sales and margin expectations weakened.

Physical AI’s data bottleneck: Why might purchases of collection hardware scale up before robots?

The material identifies high-quality training data as an industrial bottleneck for physical AI, with opportunities concentrated in collection hardware, real-world data and simulation services. Estimates point to steep growth in market size, but companies are at markedly different stages of realization, from having made sales or accumulated data to having disclosed no revenue yet.